References
- Patidar KR, Jasmohan SB. Covert and overt hepatic encephalopathy: diagnosis and management. J Clin Exp Hepatol. 2015;13(12):2048–2061.
- Riordan SM, Roger W. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337(7):473–479.
- Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–1081.
- Conn H, Lieberthal M. The hepatic coma syndromes and lactulose. Baltimore: Williams & Wilkins; 1979.
- Tapper EB, Henderson JB, Parikh ND, et al. Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans with cirrhosis. Hepatol Commun. 2019 Sept 6;3(11):1510–1519.
- Romoli M, Mazzocchetti P, D’Alonzo R, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol. 2019;17(10):926–946.
- Laffi G, La Villa G, Carloni V, et al. Loop diuretic therapy in liver cirrhosis with ascites. J Cardiovasc Pharmacol. 1993;22(Suppl 3):S51–8.
- Neff G, Zachry W. Systematic review of the economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin. Pharmacoeconomics. 2018;36(7):809–822.
- Bajaj JS, Wade JB, Gibson DP, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol. 2011;106(9):1646–1653.
- Nguyen GC, Dorry LS, Paul JT. Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepatol. 2007;5(9):1092–1099.
- Poordad FF. The burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25:3–9.
- Stepanova M, Alita M, Chapy V, et al. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol. 2012;10(9):1034–1041.
- CPI inflation calculator [Internet]. [cited 2021 Apr 28]. Available from: https://www.bls.gov/data/inflation_calculator.htm
- Austin PC, Merlo J. Intermediate and advanced topics in multilevel logistic regression analysis. Stat Med. 2017;36(20):3257–3327.
- Shaheen AA, Nguyen HH, Congly SE, et al. Nationwide estimates and risk factors of hospital readmission in patients with cirrhosis in the United States. Liver Int. 2019;39(5):878–884.
- Vadhariya A, Chen H, Serna O, et al. A retrospective study of drug utilization and hospital readmissions among medicare patients with hepatic encephalopathy. Medicine (Baltimore). 2020;99(16):e19603.
- Montagnese S, Amato E, Schiff S, et al. A patients’ and caregivers’ perspective on hepatic encephalopathy. Metab Brain Dis. 2012;27(4):567–572.